Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
Corvus Pharmaceuticals Announces Initiation Of Placebo-Controlled Phase 1 Clinical Trial Of Soquelitinib For Atopic Dermatitis
Corvus Pharmaceuticals宣佈啓動索克利替尼治療特應性皮炎的安慰劑對照的1期臨床試驗
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor
特應性皮炎是該公司的選擇性ITK抑制劑索克利替尼臨床研究的第一個免疫疾病適應症
Corvus anticipates releasing initial clinical data from trial before year-end 2024
Corvus預計將在2024年年底之前發佈試驗的初步臨床數據